459 related articles for article (PubMed ID: 27310463)
21. Cnf1 Variants Endowed with the Ability to Cross the Blood-Brain Barrier: A New Potential Therapeutic Strategy for Glioblastoma.
Colarusso A; Maroccia Z; Parrilli E; Germinario EAP; Fortuna A; Loizzo S; Ricceri L; Tutino ML; Fiorentini C; Fabbri A
Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32375387
[TBL] [Abstract][Full Text] [Related]
22. Overcoming Barriers in Glioblastoma-Advances in Drug Delivery Strategies.
Ter Linden E; Abels ER; van Solinge TS; Neefjes J; Broekman MLD
Cells; 2024 Jun; 13(12):. PubMed ID: 38920629
[TBL] [Abstract][Full Text] [Related]
23. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
Agarwal S; Muniyandi P; Maekawa T; Kumar DS
Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
[TBL] [Abstract][Full Text] [Related]
24. Erlotinib: early clinical development in brain cancer.
Addeo R; Zappavigna S; Parlato C; Caraglia M
Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
[TBL] [Abstract][Full Text] [Related]
25. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF
Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290
[TBL] [Abstract][Full Text] [Related]
26. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.
Jena L; McErlean E; McCarthy H
Drug Deliv Transl Res; 2020 Apr; 10(2):304-318. PubMed ID: 31728942
[TBL] [Abstract][Full Text] [Related]
27. Focused Ultrasonography-Mediated Blood-Brain Barrier Disruption in the Enhancement of Delivery of Brain Tumor Therapies.
Zaki Ghali MG; Srinivasan VM; Kan P
World Neurosurg; 2019 Nov; 131():65-75. PubMed ID: 31323404
[TBL] [Abstract][Full Text] [Related]
28. Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine.
Martins C; Sarmento B
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1893. PubMed ID: 37186374
[TBL] [Abstract][Full Text] [Related]
29. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
[TBL] [Abstract][Full Text] [Related]
30. Penetrating the Blood-Brain Barrier by Self-Assembled 3D DNA Nanocages as Drug Delivery Vehicles for Brain Cancer Therapy.
Tam DY; Ho JW; Chan MS; Lau CH; Chang TJH; Leung HM; Liu LS; Wang F; Chan LLH; Tin C; Lo PK
ACS Appl Mater Interfaces; 2020 Jul; 12(26):28928-28940. PubMed ID: 32432847
[TBL] [Abstract][Full Text] [Related]
31. Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting.
Martins C; Araújo M; Malfanti A; Pacheco C; Smith SJ; Ucakar B; Rahman R; Aylott JW; Préat V; Sarmento B
Small; 2023 Jun; 19(22):e2300029. PubMed ID: 36852650
[TBL] [Abstract][Full Text] [Related]
32. Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models.
Kovacs Z; Werner B; Rassi A; Sass JO; Martin-Fiori E; Bernasconi M
J Control Release; 2014 Aug; 187():74-82. PubMed ID: 24878186
[TBL] [Abstract][Full Text] [Related]
33. Overcoming the blood brain barrier in glioblastoma: Status and future perspective.
Ahmed MH; Canney M; Carpentier A; Idbaih A
Rev Neurol (Paris); 2023 Jun; 179(5):430-436. PubMed ID: 37062676
[TBL] [Abstract][Full Text] [Related]
34. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment.
Ganipineni LP; Danhier F; Préat V
J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958
[TBL] [Abstract][Full Text] [Related]
35. Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics.
Wang K; Zhang F; Wen C; Huang Z; Hu Z; Zhang Y; Hu F; Wen L
Oncol Res; 2021; 29(5):351-363. PubMed ID: 37305160
[TBL] [Abstract][Full Text] [Related]
36. Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier.
Lim SH; Yee GT; Khang D
Int J Nanomedicine; 2024; 19():2529-2552. PubMed ID: 38505170
[TBL] [Abstract][Full Text] [Related]
37. Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.
D'Amico RS; Khatri D; Reichman N; Patel NV; Wong T; Fralin SR; Li M; Ellis JA; Ortiz R; Langer DJ; Boockvar JA
J Neurooncol; 2020 Apr; 147(2):261-278. PubMed ID: 32076934
[TBL] [Abstract][Full Text] [Related]
38. Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives.
Beccaria K; Canney M; Bouchoux G; Puget S; Grill J; Carpentier A
Neurosurg Focus; 2020 Jan; 48(1):E10. PubMed ID: 31896084
[TBL] [Abstract][Full Text] [Related]
39. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
[TBL] [Abstract][Full Text] [Related]
40. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.
Bastiancich C; Danhier P; Préat V; Danhier F
J Control Release; 2016 Dec; 243():29-42. PubMed ID: 27693428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
